2 Park Drive
Unit 15
Bundoora, VIC 3083
Australia
61 3 9479 5159
https://www.adalta.com.au
Sector(s):
Industry:
Full-time employees: 10
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D. | CEO, MD & Director | 398.86k | N/A | N/A |
Mr. Angus Tester Ph.D. | Senior Director of Operations | N/A | N/A | N/A |
Ms. Janette Dixon | Head of Business Development | N/A | N/A | N/A |
Mr. Cameron Jones C.A. | Company Secretary | N/A | N/A | N/A |
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.
AdAlta Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.